VIP Peptide in NYC: The Anti-Inflammatory Neuropeptide for Chronic Illness and Gut Health
Vasoactive Intestinal Peptide—VIP—is one of the most fascinating and clinically underutilized peptides in integrative and regenerative medicine. A naturally occurring neuropeptide produced throughout the body, VIP plays crucial roles in immune regulation, inflammation control, and gut function. For patients struggling with complex chronic illness in New York City, VIP peptide therapy represents a sophisticated tool that goes well beyond what conventional approaches offer.
What Is VIP?
VIP (Vasoactive Intestinal Peptide) is a 28-amino acid neuropeptide found in the central and peripheral nervous systems, lungs, gut, and immune cells. Despite its name, its effects extend far beyond vasodilation. VIP:
- Suppresses pro-inflammatory cytokines (TNF-α, IL-6, IL-12, IFN-γ)
- Promotes anti-inflammatory mediators (IL-10, TGF-β)
- Regulates immune tolerance—shifting immune responses from Th1/Th17 inflammatory patterns toward regulatory T cell activity
- Protects neuronal tissue and supports neuroplasticity
- Modulates gut motility and secretion—VIP is one of the primary neurotransmitters of the enteric nervous system
- Supports circadian rhythm regulation through its role in the suprachiasmatic nucleus
- Promotes bronchodilation and reduces airway inflammation in the lungs
Where VIP Is Produced and Why It Can Become Depleted
Under normal circumstances, the body produces VIP continuously in the hypothalamus, gut wall, pancreas, and throughout peripheral nervous tissue. VIP levels can become suppressed in several clinically important scenarios:
Mold toxin illness (CIRS): Chronic Inflammatory Response Syndrome, triggered by water-damaged building exposure, is one of the most common settings for VIP deficiency. Mold biotoxins suppress VIP production via hypothalamic inflammation, contributing to the multi-system symptom complex characteristic of CIRS.
Chronic infections: Certain persistent infections—Lyme disease, Bartonella, viral illness—can suppress VIP through sustained neuroinflammatory signaling.
Inflammatory bowel conditions: VIP deficiency in the gut is implicated in IBS, IBD, and intestinal dysmotility.
Post-COVID syndrome: Emerging evidence suggests that VIP pathway dysregulation may contribute to long COVID symptoms including fatigue, brain fog, and autonomic dysfunction.
VIP Peptide Therapy: How It Works
Intranasal VIP administration (delivered via a nasal spray that bypasses the blood-brain barrier) is the primary therapeutic delivery route for VIP peptide therapy in chronic illness protocols. Intranasal delivery allows direct access to hypothalamic VIP receptors and rapid central anti-inflammatory effect.
Published clinical protocols, particularly those developed by Dr. Ritchie Shoemaker for CIRS treatment, document intranasal VIP use at 50mcg four times daily as part of structured biotoxin illness treatment. VIP administration in these protocols follows completion of earlier phases (antifungal treatment, cholestyramine or welchol binding, and MMP-9 normalization).
VIP in Gut Health
For patients with gut-predominant symptoms—IBS-like patterns, intestinal dysmotility, visceral hypersensitivity, or inflammatory bowel disease—VIP's enteric nervous system effects are clinically relevant. RHPNY's chronic disease management approach integrates VIP therapy when indicated alongside other gut-directed interventions.
VIP and the Immune System
VIP's ability to shift immune polarization toward tolerance has attracted interest in autoimmune conditions, including rheumatoid arthritis, Crohn's disease, and multiple sclerosis. While most autoimmune VIP research remains in clinical trial phases, the mechanistic rationale is compelling and guides integrative use.
VIP as Part of the RHPNY Peptide Toolkit
At Regen Health Physicians NYC, Dr. Ajit Dhaliwal integrates VIP therapy within individualized peptide protocols for patients with complex chronic illness. VIP is rarely used in isolation—it typically complements BPC-157 for gut healing, thymosin Alpha-1 for immune modulation, and targeted interventions for specific diagnoses.
Before VIP therapy is initiated, RHPNY conducts a thorough evaluation including inflammatory biomarkers (TGF-β1, MMP-9, C4a, VEGF), visual contrast sensitivity testing if CIRS is suspected, and comprehensive metabolic assessment.
Patients with mold illness, long COVID, Lyme-related illness, or persistent gut dysfunction who are seeking a comprehensive integrative evaluation are encouraged to schedule a consultation at RHPNY.
--- This article is for informational purposes only and does not constitute medical advice. VIP peptide therapy should be supervised by a qualified physician as part of a comprehensive treatment protocol.
